Cargando…

CART cell therapy for prostate cancer: status and promise

In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly di...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Haiyuan, Pan, Jun, Guo, Zhicheng, Yang, Chunhua, Mao, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322708/
https://www.ncbi.nlm.nih.gov/pubmed/30655675
http://dx.doi.org/10.2147/OTT.S185556
_version_ 1783385638000656384
author Yu, Haiyuan
Pan, Jun
Guo, Zhicheng
Yang, Chunhua
Mao, Lijun
author_facet Yu, Haiyuan
Pan, Jun
Guo, Zhicheng
Yang, Chunhua
Mao, Lijun
author_sort Yu, Haiyuan
collection PubMed
description In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells. In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy.
format Online
Article
Text
id pubmed-6322708
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63227082019-01-17 CART cell therapy for prostate cancer: status and promise Yu, Haiyuan Pan, Jun Guo, Zhicheng Yang, Chunhua Mao, Lijun Onco Targets Ther Review In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells. In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy. Dove Medical Press 2019-01-03 /pmc/articles/PMC6322708/ /pubmed/30655675 http://dx.doi.org/10.2147/OTT.S185556 Text en © 2019 Yu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Yu, Haiyuan
Pan, Jun
Guo, Zhicheng
Yang, Chunhua
Mao, Lijun
CART cell therapy for prostate cancer: status and promise
title CART cell therapy for prostate cancer: status and promise
title_full CART cell therapy for prostate cancer: status and promise
title_fullStr CART cell therapy for prostate cancer: status and promise
title_full_unstemmed CART cell therapy for prostate cancer: status and promise
title_short CART cell therapy for prostate cancer: status and promise
title_sort cart cell therapy for prostate cancer: status and promise
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322708/
https://www.ncbi.nlm.nih.gov/pubmed/30655675
http://dx.doi.org/10.2147/OTT.S185556
work_keys_str_mv AT yuhaiyuan cartcelltherapyforprostatecancerstatusandpromise
AT panjun cartcelltherapyforprostatecancerstatusandpromise
AT guozhicheng cartcelltherapyforprostatecancerstatusandpromise
AT yangchunhua cartcelltherapyforprostatecancerstatusandpromise
AT maolijun cartcelltherapyforprostatecancerstatusandpromise